BioAge to start the phase 2 trial of BGE-175, which can reverse the effect of immunity aging amongst elderly population, to treat COVID-19.
AiCure to join hands with OncoBay Clinical, a contract research organization, to provide oncology sponsors with scalable, AI-powered insights to improve patient care and optimize drug development.
Author Credits: Abhishek Verma, Hetal Singh
Report ID: 3859
Published Date: Apr 20, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factor driving the growth of the AI-based clinical trials solution provider market is the increasing adoption of AI-based platforms to enhance the accuracy and productivity of clinical trials at different stages.
The market is anticipated to attain a CAGR of 22% over the forecast period, i.e., 2023-2035.
Strict regulations around the globe are one of the key challenges affecting market growth.
The market in North America is projected to hold the largest market share in the forecast period owing to increasing penetration of AI-based tools and increasing government initiatives for adoption in different medical projects.
The major players in the market are Unlearn.AI, Inc., Saama Technologies, LLC, Biosymetrics, Pharmaceutical Pipeline Enhancement Stategies, LLC, Deep 6 AI Inc., Innoplexus, Mendel.ai, Intellengencia, Median Technologies, and others.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by clinical trial phase, application, end user, and region.
The oncology segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.